Biosensor Recession proof -heartstent biz

Biosensors 1Q 2013  result on 25/7/12, interest just starting.

Emerging mid-cap companies such as Biosensors have also pulled back to attractive valuations on increased risk aversion. We reaffirm Buy on Biosensors.

- Nomura Research today

Biosensors AGM on 26/7/12, can someone raise this question:
The companany has beem profitable for more than 3 years, is it time to declare divident pay out policy?
I believe Biosensors can grow to become potential gem.

The group is proposing a share buyback mandate in its AGM on 26 July.

Biosensors: Goldman Sachs initiates at Buy with TP $1.48, says with the stock trading at a two year low and 19% discount to global peers, it has fuly priced in a potential decline in Japan sales after the latest price cuts. Believes the risk / reward is skewed to the upside based on potential for, i) strong growth in the EU (+8%), APAC / Latam (+21%) and China (+15%), driving a 16% earnings CAGR over FY13-15e on mkt share gains, and ii) regulatory approvals for BioFreedom in the EU and BioMatrix in China, which would be catalysts for re-rating.

@ $1.24 liao.
Another 24 cents to go to Goldman Sachs target.